Venture Capital
Make investment decisions with a clearer view of the science, technology and commercial assumptions behind genomics and biotechnology ventures.
For venture capital firms, angel investors and family offices, I bring technical due-diligence and entrepreneurial experience to the questions that matter: whether the science is plausible, what differentiates the platform, and which risks deserve closer scrutiny.
From an attractive pitch to informed investment scrutiny
- Test scientific and AI-related claims against the evidence and technical requirements.
- Identify strengths, limitations and questions across the platform, product, data and business model.
- Put investment choices in context, with attention to market relevance, defensibility and highly scalable implementation.
The approach is lean and Agile, focused on impactful, effective advice that distinguishes transformative potential from an attractive claim and identifies the step-wise change needed to realise it. Support can include technical due diligence, an independent second opinion, investment-committee questions and written findings or recommendations, with the scope agreed around the opportunity.
Relevant investment experience
The work combines scientific scrutiny with an understanding of product, data, teams and commercial reality. Selected examples include:
- Helped a small biotechnology company raise £1.8 million in seed funding by evaluating competitors, shaping its data strategy, co-authoring the pitch and clarifying the technical advantage and roadmap.
- Co-wrote a successful US National Institutes of Health grant worth $1,440,191 and has helped secure further research funding, scholarships and technical studentships.
- Built and assessed production-grade genomics and multi-omics systems used in clinical care, biomarker discovery, cancer stratification and drug discovery—experience that helps distinguish a credible platform from an attractive claim.
- Technical due diligence for a VC for investments of £1–5 million.
Did you know?
In 2024, Labcorp announced a USD 239 million winning bid for selected Invitae assets through a bankruptcy protection process. A recognised name and sophisticated technology do not remove commercial risk. Before committing capital, scrutinise the business model and route to scale as carefully as the science.
Support can include
- Technical due diligence of biotech and genomics companies
- Assessment of scientific claims and technical feasibility
- Review of platform technologies, pipelines and defensibility
- Evaluation of AI-biology and computational biology claims
- Founder, product and market-risk assessment
- Strategic questions for investment committees
- Independent second opinions before investment decisions
- Experienced serial founder with an extensive contact network in the sector.
- Global exposure across resource-rich and resource-poor environments, from Qatar and Sweden to the UK and Malawi.
What colleagues and collaborators say
Excerpts from LinkedIn recommendations.
“We worked with Magdalena on potential new investments, leveraging her genetic knowledge. We found her knowledge impressive and she was extremely user friendly in all respects, including work rate, quality of output and ease of communication.”
“She possesses a deep technical understanding and excels in product development, seamlessly bridging the gap between complex technical requirements and customer needs.”
What do you need to know before deciding?
Book a meeting to discuss the company or platform, your investment stage and the questions you need answered. You can also send an enquiry outlining the opportunity.